Centogene and Takeda extend partnership for LSD diagnostics By Investing.com
[ad_1]
© Reuters.
CAMBRIDGE, Mass. – Centogene N.V. (NASDAQ:CNTG), a life science company specializing in rare and neurodegenerative diseases, has announced the extension of its partnership with pharmaceutical giant Takeda (TSE:4502/NYSE:TAK). The collaboration aims to provide diagnostic testing for Lysosomal Storage Disorders (LSDs) to patients worldwide.
The agreement, which builds on a relationship initiated in January 2015 with Shire Pharmaceuticals prior to its acquisition by Takeda in 2019, ensures continued access to Centogene’s diagnostic capabilities. These tests are critical for the early detection of LSDs, which include conditions such as Fabry disease, Gaucher disease, and Hunter syndrome.
Ian Rentsch, Centogene’s Chief Commercial Officer and General Manager – Pharma, emphasized the importance of the extended partnership in expediting the diagnosis of LSD patients globally. Kim Stratton, CEO of Centogene, also highlighted the company’s commitment to collaborating with global players to deliver life-changing answers to patients with rare and neurodegenerative diseases.
Centogene’s approach integrates multiomic technologies with its extensive Biodatabank, aiming to guide precision medicine and improve health outcomes. Its network includes approximately 30,000 active physicians, and its Biodatabank represents over 800,000 patients from more than 120 countries.
The company’s expertise in genomic and multiomic testing is considered vital for underserved patient communities, particularly those affected by rare diseases. Centogene’s laboratories, certified by ISO, CAP, and CLIA, utilize a range of datasets to support the diagnosis and research into rare conditions.
The renewed partnership with Takeda is expected to continue facilitating rapid and reliable diagnostics, which are essential for early intervention and treatment of LSDs. This collaboration underscores the role of strategic partnerships in advancing healthcare for rare disease patients.
The announcement of this extended partnership is based on a press release statement from Centogene N.V.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
[ad_2]
Source link
© Reuters.
CAMBRIDGE, Mass. – Centogene N.V. (NASDAQ:CNTG), a life science company specializing in rare and neurodegenerative diseases, has announced the extension of its partnership with pharmaceutical giant Takeda (TSE:4502/NYSE:TAK). The collaboration aims to provide diagnostic testing for Lysosomal Storage Disorders (LSDs) to patients worldwide.
The agreement, which builds on a relationship initiated in January 2015 with Shire Pharmaceuticals prior to its acquisition by Takeda in 2019, ensures continued access to Centogene’s diagnostic capabilities. These tests are critical for the early detection of LSDs, which include conditions such as Fabry disease, Gaucher disease, and Hunter syndrome.
Ian Rentsch, Centogene’s Chief Commercial Officer and General Manager – Pharma, emphasized the importance of the extended partnership in expediting the diagnosis of LSD patients globally. Kim Stratton, CEO of Centogene, also highlighted the company’s commitment to collaborating with global players to deliver life-changing answers to patients with rare and neurodegenerative diseases.
Centogene’s approach integrates multiomic technologies with its extensive Biodatabank, aiming to guide precision medicine and improve health outcomes. Its network includes approximately 30,000 active physicians, and its Biodatabank represents over 800,000 patients from more than 120 countries.
The company’s expertise in genomic and multiomic testing is considered vital for underserved patient communities, particularly those affected by rare diseases. Centogene’s laboratories, certified by ISO, CAP, and CLIA, utilize a range of datasets to support the diagnosis and research into rare conditions.
The renewed partnership with Takeda is expected to continue facilitating rapid and reliable diagnostics, which are essential for early intervention and treatment of LSDs. This collaboration underscores the role of strategic partnerships in advancing healthcare for rare disease patients.
The announcement of this extended partnership is based on a press release statement from Centogene N.V.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
About The Author
